SCHEMBL22367672

SCHEMBL22367672

O=P(O)(O)Oc1ccccc1Oc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.63
KDM4E B2RXH2 1/20 0.56
USP2 O75604 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
PDE3A Q14432 1/20 0.56
HSD17B10 Q99714 1/20 0.56
INPPL1 O15357 6/20 0.53
INPP5A Q14642 5/20 0.53
INPP5B P32019 2/20 0.53
CTNNB1 P35222 1/20 0.47
AKT1 P31749 1/20 0.47
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28655315 0.85 INPPL1 (0.61) SRCKDM4EUSP2ALDH1A1HPGD
SCHEMBL2573126 0.85 INPPL1 (0.70) SRCKDM4EUSP2ALDH1A1HPGD
SCHEMBL7906266 0.83 LMNA (0.48) SRCALDH1A1HPGDCTNNB1TSHR
SCHEMBL28441446 0.82 SRC (0.61) SRCKDM4EUSP2ALDH1A1HPGD
SCHEMBL11548382 0.80 LMNA (0.46) SRCALDH1A1HPGDCTNNB1TSHR
SCHEMBL8388043 0.79 SRC (0.83) SRCINPPL1INPP5ATSHRL3MBTL1
Phenyl Dihydrogen Phosphate SCHEMBL28311333 0.78 SRC (1.00) SRCKDM4EUSP2ALDH1A1HPGD
Phenyl Dihydrogen Phosphate SCHEMBL20263 0.78 SRC (1.00) SRCKDM4EUSP2ALDH1A1HPGD
SCHEMBL51822 0.78 LTA4H (0.69) ALDH1A1HPGDCTNNB1TSHRLMNA
SCHEMBL11548387 0.77 LMNA (0.43) SRCALDH1A1HPGDCTNNB1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12311030-B2 Antibody-sting agonist conjugates and their use in immunotherapy IMMUNESENSOR THERAPEUTICS, INC. (US) 2025-05-27 US disclosed
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK A/S (DK) 2025-05-08 US disclosed
EP-4479402-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2024-12-25 EP disclosed
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) 2024-04-18 US disclosed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed
WO-2023155004-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2023-08-24 WO disclosed
US-20220177510-A1 DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) 2022-06-09 US disclosed
EP-3999118-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY Immunesensor Therapeutics, Inc. (US) 2022-05-25 EP disclosed
US-20220105198-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. 2022-04-07 US disclosed
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-11-30 US disclosed
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-10-19 US disclosed
US-20210290774-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-09-23 US disclosed
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
WO-2021016204-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-01-28 WO disclosed
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-01-21 US disclosed
WO-2020216327-A1 DERIVATIVES OF GLYCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2020-10-29 WO disclosed
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 LUMINEX INTERNATIONAL (CN) 2020-09-10 US disclosed
EP-3700536-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) 2020-09-02 EP disclosed
CN-106147159-B A kind of low addition type halogen-free flame retardant polylactic acid composite material and preparation method thereof 马德里高等材料研究院 2018-09-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210290774-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS SRC 2340/4885KDM4E 3364/4885USP2 2793/4885
US-20220177510-A1 DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE GALK1, PHKA1, PGK1 SRC 1806/4885KDM4E 3561/4885USP2 3341/4885
US-20220105198-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS SRC 2340/4885KDM4E 3364/4885USP2 2793/4885
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, TRPV1 SRC 884/4885KDM4E 2777/4885USP2 4098/4885
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy STING1, CGAS, MAVS SRC 2340/4885KDM4E 3364/4885USP2 2793/4885
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885
US-12311030-B2 Antibody-sting agonist conjugates and their use in immunotherapy STING1, CGAS, MAVS SRC 2340/4885KDM4E 3364/4885USP2 2793/4885
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS SRC 2340/4885KDM4E 3364/4885USP2 2793/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA SRC 924/4885KDM4E 3885/4885USP2 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.